Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 73, 101-115
Abstract
No abstract availableKeywords
Funding Information
- European Regional Development Fund
- Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición
- Ministerio de Ciencia, Innovación y Universidades
This publication has 299 references indexed in Scilit:
- Estrogen receptor beta in breast cancerMolecular and Cellular Endocrinology, 2014
- Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour propertiesNature Communications, 2013
- Cholesterol metabolism and resistance to tamoxifenCurrent Opinion in Pharmacology, 2012
- Cholesterol epoxide hydrolase and cancerCurrent Opinion in Pharmacology, 2012
- Anticancer Activity of the Cholesterol Exporter ABCA1 GeneCell Reports, 2012
- MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive reviewEMBO Molecular Medicine, 2012
- Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate PathwayCell, 2012
- Biosynthesis of Cholesterol and Other SterolsChemical Reviews, 2011
- Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Expert Reviews in Molecular Medicine, 2008
- LXR Signaling Couples Sterol Metabolism to Proliferation in the Acquired Immune ResponseCell, 2008